Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial

Affiliations

¹ Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK. Electronic address: i.kunkler@ed.ac.uk.
² Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK.
³ Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh EH4 2XU, UK.

Comment

Ian Kunkler et al. Lancet. 2024.

. 2024 Aug 10;404(10452):525.

doi: 10.1016/S0140-6736(24)01361-8.

¹ Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK. Electronic address: i.kunkler@ed.ac.uk.
² Institute of Genetics and Cancer, University of Edinburgh, Edinburgh EH4 2XU, UK.
³ Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh EH4 2XU, UK.

No abstract available

Comment in

Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial - Authors' reply.
Mann GB, Rose AK, Zdenkowski N. Mann GB, et al. Lancet. 2024 Aug 10;404(10452):526. doi: 10.1016/S0140-6736(24)01362-X. Lancet. 2024. PMID: 39127480 No abstract available.

Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study.
Mann GB, Skandarajah AR, Zdenkowski N, Hughes J, Park A, Petrie D, Saxby K, Grimmond SM, Murugasu A, Spillane AJ, Chua BH, Badger H, Braggett H, Gebski V, Mou A, Collins JP, Rose AK. Mann GB, et al. Lancet. 2024 Jan 20;403(10423):261-270. doi: 10.1016/S0140-6736(23)02476-5. Epub 2023 Dec 5. Lancet. 2024. PMID: 38065194 Clinical Trial.